Daily Archives: July 29, 2022
Systematic Review | Rapid, point‐of‐care antigen tests for diagnosis of SARS‐CoV‐2 infection.
29 Jul, 2022 | 12:39h | UTCRapid, point‐of‐care antigen tests for diagnosis of SARS‐CoV‐2 infection – Cochrane Library
Summary: How accurate are rapid antigen tests for diagnosing COVID-19? – Cochrane Library
M-A | Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes.
29 Jul, 2022 | 12:37h | UTCCommentaries:
No justification for bespoke antihypertensive intervention in type 2 diabetes – medwire News
Blood pressure control according to type 2 diabetes status – The Lancet Diabetes & Endocrinology (free registration required)
Commentary on Twitter
Online—Blood pressure-lowering treatment for prevention of major #cardiovascular diseases in people with and without type 2 #diabetes: an individual participant-level data meta-analysis https://t.co/AmNxyW9Via #T2D #BloodPressure #hypertension #openaccess pic.twitter.com/NfdLktZXai
— The Lancet Diabetes & Endocrinology (@TheLancetEndo) July 25, 2022
Position Paper | Red yeast rice for dyslipidemias and cardiovascular risk reduction.
29 Jul, 2022 | 12:35h | UTC
Systematic Review | Antiplatelet agents and anticoagulants for hypertension.
29 Jul, 2022 | 12:29h | UTCAntiplatelet agents and anticoagulants for hypertension – Cochrane Library
Summary: Antiplatelet agents and anticoagulants for high blood pressure – Cochrane Library
Commentary on Twitter
Do #antiplatelet agents & #anticoagulants improve outcomes in people with #hypertension?
Our newly updated @CochraneLibrary review looks at the evidence of 6 RCTs involving more than 61,000 participants: https://t.co/zaXP4YLg4n#CochraneEvidence #blogshot pic.twitter.com/X1DK2NTCtb
— Cochrane Hypertension (@CochraneHTN) July 28, 2022
ASTRO Guideline | Radiation therapy for IDH-mutant grade 2 and grade 3 diffuse glioma.
29 Jul, 2022 | 12:33h | UTC
M-A | Lung cancer occurrence after an episode of tuberculosis.
29 Jul, 2022 | 12:28h | UTC
Guideline | Pediatric differentiated thyroid carcinoma.
29 Jul, 2022 | 12:31h | UTC
A large observational study suggests long-acting injectable antipsychotics are associated with better outcomes than oral antipsychotics in people with schizophrenia.
29 Jul, 2022 | 12:25h | UTCInvited Commentary: Improving Outcomes in Schizophrenia—A Case for Initiation of Long-Acting Antipsychotics in Early-Phase Illness – JAMA Network Open
Related:
Long-term Outcomes of Early Use of Long-Acting Injectable Antipsychotics in Schizophrenia – The Journal of Clinical Psychiatry (link to abstract – $ for full-text)
Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis – The Lancet (link to abstract – $ for full-text)
Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies – The Lancet Psychiatry (link to abstract – $ for full-text)
Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies – The Lancet Psychiatry (link to abstract – $ for full-text)
Commentary on Twitter
This case series of people with schizophrenia found long-acting injectable antipsychotics were associated with less disease relapse and hospitalization vs oral antipsychotics, w/o an increased risk of adverse events. @Esther_CSMPRHKU @HKUPharm @hkumed https://t.co/ZiPkV4lSk0
— JAMA Network Open (@JAMANetworkOpen) July 28, 2022
Cohort Study | Impact of peridevice leak on 5-year outcomes after left atrial appendage closure.
29 Jul, 2022 | 12:26h | UTCImpact of Peridevice Leak on 5-Year Outcomes After Left Atrial Appendage Closure – Journal of the American College of Cardiology (link to abstract – $ for full-text)
Commentary: Peridevice Leaks After LAA Occlusion Signal Poorer 5-Year Outcomes – TCTMD
Cohort Study | Assessment of second primary cancer risk among men receiving primary radiotherapy vs. surgery for the treatment of prostate cancer.
29 Jul, 2022 | 12:23h | UTC
Commentary on Twitter
In this cohort study of patients with localized prostate cancer, radiotherapy was associated with a small increase in the risk of developing a second primary cancer. https://t.co/YsrNo3FKwM
— JAMA Network Open (@JAMANetworkOpen) July 28, 2022
Cohort Study | Analysis of prescriptions for dual antiplatelet therapy after acute ischemic stroke.
29 Jul, 2022 | 12:20h | UTCRelated:
Commentary on Twitter
In this cohort study, dual antiplatelet of aspirin and clopidogrel was underused in patients with minor ischemic stroke and potentially overused in non-minor ischemic stroke, with substantial hospital variations. https://t.co/rZeGbMgF1E
— JAMA Network Open (@JAMANetworkOpen) July 28, 2022
M-A | Socioeconomic indicators of treatment prognosis for adults with depression.
29 Jul, 2022 | 12:17h | UTCNews Release: People without jobs or secure housing have worse outcomes when treated for depression – University College London
Commentary on Twitter
Socioeconomic disadvantage in employment and housing is associated with considerably worse outcomes in #depression, regardless of treatment type and after adjusting for clinical prognostic factors. https://t.co/bVTQv5zx8C
— JAMA Psychiatry (@JAMAPsych) May 6, 2022
Long-term results of a RCT | Active maintenance Olaparib vs. Placebo for germline BRCA-mutated metastatic pancreatic cancer.
29 Jul, 2022 | 12:18h | UTCOverall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary on Twitter
OS data from the POLO trial of maintenance olaparib vs placebo for pts with BRCA-mutant PDAC reveal no significant benefit (median 19.0 vs 19.2 months) although the curves separated at 24 months & 3-yr OS was 33.9% vs 17.8%; other outcomes favour olaparib: https://t.co/JZ28MsGV0B
— NatureRevClinOncol (@NatRevClinOncol) July 20, 2022